{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:47:50Z","timestamp":1781628470299,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Antimicrobial resistance and the rapid spread of multiresistant bacteria represent one of the main public health problem in limited resources countries. This issue is significantly worsening since the COVID-19 pandemic due to the unreasonably increased antibiotics prescription to patients with confirmed SARS-CoV-2 infection. The aim of this study was to examine whether COVID-19 pandemic (2020, 2021) was associated with increased antibiotic consumption in inpatient and outpatient settings in the middle size urban region (Republic of Srpska\/Bosnia and Herzegovina) in comparison to period before the pandemic (2019). Additionally, we aimed to determine antimicrobial resistance and the presence of multiresistant bacteria in the regional hospital (\u201cSaint Apostol Luka\u201d Hospital Doboj) in 2021.<\/jats:p><jats:p><jats:bold>Methodology:<\/jats:bold> The consumption of antibiotics in inpatient was calculated as Defined Daily Dose per one hundred of patient-days. The consumption of antibiotics in outpatient was calculated as Defined Daily Dose per thousand inhabitants per day. Resistance of bacteria to antibiotics is expressed as a rates and density for each observed antibiotic. The rate of resistance was calculated as a percentage in relation to the total number of isolates of individual bacteria. The density of resistance of isolated bacteria against a specific antibiotic was expressed as the number of resistant pathogens\/1000 patient days.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Antibiotic consumption in hospital setting registered during 2019, 2020 and 2021 was as follows: carbapenems (meropenem: 0.28; 1.91; 2.33 DDD\/100 patient-days, respectively), glycopeptides (vancomycin: 0.14; 1.09, 1.54 DDD\/100 patient-days, respectively), cephalosporins (ceftriaxone: 6.69; 14.7; 14.0 DDD\/100 patient-days, respectively) and polymyxins (colistin: 0.04; 0.25; 0.35 DDD\/100 bed-days, respectively). Consumption of azithromycin increased drastically in 2020, and dropped significantly in 2021 (0.48; 5.61; 0.93 DDD\/100 patient-days). In outpatient setting, an increase in the consumption of oral forms of azithromycin, levofloxacin and cefixime, as well as parenteral forms of amoxicillin-clavulanic acid, ciprofloxacin and ceftriaxone, was recorded. In 2021, antimicrobial resistance to reserve antibiotics in hospital setting was as follows: Acinetobacter baumanii to meropenem 66.0%, Klebsiella spp to cefotaxime 67.14%, Pseudomonas to meropenem 25.7%.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Recent COVID-19 pandemic was associated with increased antibiotic consumption in inpatient and outpatient settings, with characteristic change of pattern of azithromycin consumption. Also, high levels of antimicrobial resistance to reserve antibiotics were registered in hospital setting with low prevalence of identified pathogen-directed antimicrobial prescription. Strategies toward combat antimicrobial resistance in the Doboj region are urgently needed.<\/jats:p>","DOI":"10.3389\/fphar.2023.1067973","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:17:55Z","timestamp":1678857475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Antibiotic consumption and antimicrobial resistance in the SARS-CoV-2 pandemic: A single-center experience"],"prefix":"10.3389","volume":"14","author":[{"given":"Dragana","family":"Sokolovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Drakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Vuji\u0107\u2010Aleksi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Joksimovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini\u0161a","family":"Mari\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Ne\u017ei\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0263437","DOI":"10.1371\/journal.pone.0263437","article-title":"Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020","volume":"17","author":"Bogdani\u0107","year":"2022","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"844818","DOI":"10.3389\/fphar.2022.844818","article-title":"Consumption trends of antibiotics in Brazil during the COVID-19 pandemic","volume":"13","author":"Del Fiol","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B3","unstructured":"European Centre for disease prevention and control antimicrobial consumption database (ESAC-Net)2022"},{"key":"B4","unstructured":"Antimicrobial resistance in the EU\/EEA. A one health response2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jiph.2021.02.011","article-title":"Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?","volume":"14","author":"Ghosh","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/antibiotics10020132","article-title":"Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic","volume":"10","author":"Grau","year":"","journal-title":"Antibiot. (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/antibiotics10080943","article-title":"Antimicrobial consumption among 66 acute care hospitals in catalonia: Impact of the COVID-19 pandemic","volume":"10","author":"Grau","year":"","journal-title":"Antibiotics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14787210.2022.2011719","article-title":"Antimicrobial consumption in patients with COVID-19: A systematic review and meta-analysis","volume":"20","author":"Khan","year":"2022","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ijid.2020.12.087","article-title":"Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings","volume":"104","author":"Lucien","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/antibiotics10020182","article-title":"Antimicrobial resistance patterns and antibiotic use during hospital conversion in the COVID-19 pandemic","volume":"10","author":"Martinez-Guerra","year":"2021","journal-title":"Antibiotics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/life11100996","article-title":"COVID-19 and antimicrobial resistance: Data from the Greek electronic system for the surveillance of antimicrobial resistance-WHONET-Greece (january 2018-march 2021)","volume":"11","author":"Polemis","year":"2021","journal-title":"Life (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3390\/antibiotics11060810","article-title":"Pattern of antibiotic use among hospitalized patients according to WHO access, watch, reserve (AWaRe) classification: Findings from a point prevalence survey in Bangladesh","volume":"11","author":"Rashid","year":"2022","journal-title":"Antibiotics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/jac\/dkaa194","article-title":"COVID-19 and the potential long-term impact on antimicrobial resistance","volume":"75","author":"Rawson","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2200803","DOI":"10.1183\/13993003.00803-2022","article-title":"Update june 2022: Management of hospitalised adults with coronavirus disease 2019 (COVID-19): A European respiratory society living guideline","volume":"60","author":"Roche","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/antibiotics11101319","article-title":"Consumption of antibiotics in primary care setting before and during COVID-19 pandemic in republic of Srpska, Bosnia and Herzegovina","volume":"11","author":"Sokolovi\u0107","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40264-020-00976-7","article-title":"Azithromycin in COVID-19 patients: Pharmacological mechanism, clinical evidence and prescribing guidelines","volume":"43","author":"Sultana","year":"2020","journal-title":"Drug Saf."},{"key":"B17","unstructured":"Antimicrobial stewardship programmes in health-care facilities in low-and middle-income countries: A WHO practical toolkit"},{"key":"B18","unstructured":"AWaRe classification antibiotics"},{"key":"B19","unstructured":"GLASS guide for national surveillance systems for monitoring antimicrobial consumption in hospitals2020"},{"key":"B20","unstructured":"Global action plan on antimicrobial resistance2015"},{"key":"B21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1067973\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:18:02Z","timestamp":1678857482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1067973\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":21,"alternative-id":["10.3389\/fphar.2023.1067973"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1067973","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"article-number":"1067973"}}